Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tony Johnson

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
International Journal of Geriatric Psychiatry|October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)Martin Knapp, Derek King, Renée Romeo, et al.
Diabetes|November 21, 2007
Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese menUlf Risérus, Dennis Sprecher, Tony Johnson, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
Bioorganic & Medicinal Chemistry|October 22, 2020
Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitorsSébastien L Degorce, Anna Aagaard, Rana Anjum, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2013
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1Christopher A Hurley, Wade S Blair, Richard J Bull, et al.
The New England Journal of Medicine|March 9, 2012
Donepezil and memantine for moderate-to-severe Alzheimer's diseaseRobert Howard, Rupert McShane, James Lindesay, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
Journal of Medicinal Chemistry|May 18, 2012
Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitorsJanusz J Kulagowski, Wade Blair, Richard J Bull, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
International Journal of Geriatric Psychiatry|October 15, 2016
Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial)Martin Knapp, Derek King, Renée Romeo, et al.
Diabetes|November 21, 2007
Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese menUlf Risérus, Dennis Sprecher, Tony Johnson, et al.
The Lancet. Neurology|October 31, 2015
Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analysesRobert Howard, Rupert McShane, James Lindesay, et al.
Bioorganic & Medicinal Chemistry|October 22, 2020
Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitorsSébastien L Degorce, Anna Aagaard, Rana Anjum, et al.
International Journal of Geriatric Psychiatry|September 18, 2010
Determining the minimum clinically important differences for outcomes in the DOMINO trialRobert Howard, Patrick Phillips, Tony Johnson, et al.
Bioorganic & Medicinal Chemistry Letters|May 7, 2013
Novel triazolo-pyrrolopyridines as inhibitors of Janus kinase 1Christopher A Hurley, Wade S Blair, Richard J Bull, et al.
The New England Journal of Medicine|March 9, 2012
Donepezil and memantine for moderate-to-severe Alzheimer's diseaseRobert Howard, Rupert McShane, James Lindesay, et al.
Trials|July 28, 2009
DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCTRob Jones, Bart Sheehan, Patrick Phillips, et al.
Journal of Medicinal Chemistry|May 18, 2012
Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitorsJanusz J Kulagowski, Wade Blair, Richard J Bull, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Pageof 6